A multi-centre, randomised, placebo-controlled, doubleblind, parallel-group trial to evaluate safety and efficacy of spesolimab [BI 655130] in adult patients with ulcerative pyoderma gangrenosum [PG] who require systemic therapy (NCT06624670)
Bi 1368-0140
This trial is Currently recruiting
Registration number NCT06624670
Program & service
This trial is being run with the Specialty Medicine service, and as part of the Dermatology program.
Trial phase
Phase 3
Trial participation type
This trial has been designed for the Clinical Research of a Drug.
Principal investigator
Professor Johannes S Kern
More information
To find out more about this clinical trial, please review full details on the ANZCTR website.
View on ANZCTRIf you would like further details or have any questions about this clinical trial, we encourage you to get in touch with us and a member of our team will be happy to provide you with more information.